QINGDAO PORT (06198) plans to invest 6.615 billion yuan to construct the Dongjiakou general wharf project.
Qingdao Port (06198) announced that in order to enhance the throughput capacity of the port, optimize the production layout, meet the operational needs of the port, and serve the national strategic security, the company plans to invest in the construction of the Dongjiakou General-purpose Wharf Project. The estimated investment for the project is approximately 6.615 billion RMB.
Qingdao Port (06198) announced that, in order to improve the port's cargo handling capacity, optimize production layout, meet port operation needs, and support national strategic services, the company plans to invest in the construction of the Dongjiakou General-purpose Terminal Project, with an estimated investment of approximately RMB 6.615 billion.
The project will be located at the Langyatou Bay in the Dongjiakou Port Area, with the construction of 7 general-purpose berths for 30,000-70,000 tonnage vessels. This includes the construction of 4 30,000 tonnage berths on the north side of the bay, 2 40,000 tonnage berths and 1 70,000 tonnage berth on the east side of the bay. The total length of the terminal shoreline is 1,668 meters, with a total land area of 109.5329 hectares (including 106.1380 hectares of reclaimed land and 3.3949 hectares of permeable structures), and a designed annual handling capacity of 14.33 million tons.
This project aligns with the company's strategic development plan and is of great significance in promoting the company's long-term development. The Dongjiakou General-purpose Terminal Project will serve as an important support for the general cargo handling operations in the Dongjiakou Port Area, facilitating the handling of certain types of bulk and general cargo transferred from the Qianwan Port Area and Dagang Port Area. This will better serve the transportation needs of grain and oil processing, steel, timber, automotive, and equipment goods in the vicinity of the port, thereby enhancing the company's competitiveness and profitability. It will not have a significant adverse impact on the company's finances and operations, and will not harm the interests of the company and its shareholders, especially small and medium shareholders.
Related Articles
.png)
IPO news | Keen Gene submits application to Hong Kong Stock Exchange

JACOBIO-B(01167) subsidiary enters into licensing and collaboration agreement with AstraZeneca to develop and commercialize the pan-KRAS inhibitor JAB-23E73.

China Securities Co., Ltd.: Three clues for A-share investment at the end of the year and the beginning of the year.
IPO news | Keen Gene submits application to Hong Kong Stock Exchange
.png)
JACOBIO-B(01167) subsidiary enters into licensing and collaboration agreement with AstraZeneca to develop and commercialize the pan-KRAS inhibitor JAB-23E73.

China Securities Co., Ltd.: Three clues for A-share investment at the end of the year and the beginning of the year.






